Summary & Overview
HCPCS J8521: Capecitabine, Oral, 500 mg
HCPCS Level II code J8521 denotes capecitabine, oral, 500 mg, a commonly prescribed oral chemotherapeutic agent. This code identifies the drug product for pharmacy billing and medical claims for outpatient dispensing of capecitabine. Nationally, accurate coding of oral oncology agents matters for benefit administration, patient cost-sharing, and monitoring of utilization and safety across payers.
Key payers in scope include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise briefing on the clinical role of capecitabine, the claim contexts where J8521 is used, and which payer types commonly process these claims. The publication summarizes benchmarks and billing considerations tied to oral chemotherapy dispensing, common modifiers used in pharmacy and medical claims, and implications for reimbursement workflows.
The analysis covers payment and coverage framing rather than clinical guidance: how J8521 appears on pharmacy and medical service lines, typical sites of service, and areas where policy updates or coding guidance can affect claims processing and patient cost responsibility. Data limits and specific payer rates are noted where available.
Billing Code Overview
HCPCS Level II code J8521 represents capecitabine, oral, 500 mg, an oral antineoplastic agent used in chemotherapy regimens for certain cancers. The service type is oral chemotherapy drug administration (pharmacy-dispensed medication). The typical site of service is outpatient pharmacy or clinic dispensing for take-home oral chemotherapy, including hospital outpatient departments, infusion centers that dispense oral agents, and retail or specialty pharmacies.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with stage III colon adenocarcinoma is prescribed oral capecitabine as adjuvant chemotherapy following surgical resection. The medication billed under J8521 is dispensed by an ambulatory oncology infusion pharmacy or outpatient specialty pharmacy and taken by the patient at home in scheduled cycles (commonly 14 days on, 7 days off). Clinical workflow includes chemotherapy ordering in the electronic medical record, verification by an oncology pharmacist, patient counseling on dosing and toxicities (hand-foot syndrome, diarrhea, myelosuppression), documentation of weight and renal function prior to each cycle, dispensing with appropriate labeling, and periodic oncology clinic visits for toxicity assessment and dose adjustments. Typical sites of service include outpatient infusion centers, hospital outpatient pharmacies, and specialty pharmacy dispensing with home administration by the patient.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 | Professional component | Use when reporting a separate professional service component related to the dispensing encounter if applicable (rare for drug-only billing). |
22 |